Please use this identifier to cite or link to this item:
|Title:||An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy.|
|Authors:||Di Bartolo, N|
|Citation:||Di Bartolo, N., Smith, S. V., Hetherington, E., & Sargeson, A. (2009). An investigation into the potential of SarAr for use in Cu-64 radioimmunotherapy. Australian Journal of Chemistry, 62(10), 1261-1270. doi:10.1071/CH09369|
|Abstract:||The B72.3 monoclonal antibody was radiolabelled with 123I, and with 111In and 64Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using 131I, 90Y, 67Cu, and 64Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the 64Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as 131I, 90Y, and 67Cu. © 2009, CSIRO Publishing|
|Gov't Doc #:||1585|
|Appears in Collections:||Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.